Patent · US Expired

Adjuvant theraphy of G250-expressing tumors

US7691375B2 · kind B2 · utility

2Cited by

0References

18Claims

0Family size

Assignee

Wilex AG · DE

Inventors

Olaf Wilhelm · Birkenfeld, DE
Sven Warnaar · Leiden, NL

Key dates

Filing date	Jun 29, 2005
Grant date	Apr 6, 2010
Priority date	—
Expiry date	Apr 12, 2026

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/24
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The invention relates to a method for the treatment of G250-antigen-expressing tumors, in particular renal clear cell carcinoma comprising the administration of G250-antigen-specific antibodies to high-risk patients diagnosed with non-metastasizing disease.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.